Long-term follow-up of retroviral vector-administered interferon-γ(IFN-γ) gene in metastatic melanoma

Cancer Gene Therapy

Volumn 7, Issue 10, 2000, Pages 1297-1298

  Nemunaitis, J ^a,b   Buchanan, A ^a   Jolly, D J ^c  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; VIRUS VECTOR;

CANCER SURVIVAL; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GENE THERAPY; HUMAN; IMMUNOREACTIVITY; LETTER; LONG TERM CARE; MELANOMA; METASTASIS; PRIORITY JOURNAL; RETROVIRUS; TREATMENT OUTCOME; VIRUS REPLICATION;

UNIDENTIFIED RETROVIRUS;

EID: 0033764794     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.0240     Document Type: Letter

References (7)

1. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or interferon-γ
2. A phase I clinical trial of immunotherapy with γ-IFN gene-modified autologous melanoma cells: Monitoring the humoral immune response
3. Phase I trial of retroviral vector-mediated interferon (IFN)-γ gene transfer into autologous tumor cells in patients with metastatic melanoma
4. Phase I trial of interferon-γ (IFN-γ) retroviral vector administered intratumorally to patients with metastatic melanoma
5. Phase I trials of γ-interferon (γ-IFN) retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma
6. Induction of anti-melanoma-associated antigen systemic immunity on intratumor delivery of γ-interferon (γ-IFN) retroviral vector in melanoma patients
7. Retrovirus-mediated gene transfer of the human γ-IFN gene: A therapy for cancer